Global Synthetic Biology Tools Industry Analysis, Top Company, Research Forecast, Analysis and Supply Demand …Healthcare JournalProduct Overview and Scope of Synthetic Biology Tools, Synthetic Biology Tools Segment by Type (Product Category) and Appl… Continue reading
Synthetic Biology Sales Market Competitive Landscape, Trends, Market Concentration Rate, Business Strategies 2022The Truth TodayGlobal Synthetic Biology Sales Market Research Report 2017 provides a unique tool for evaluating the market, highlighting op… Continue reading
STAT |
Scientists are thinking the unthinkable: CRISPR might one day reverse devastating brain diseases
STAT It may seem unlikely, then, that such a devastating condition is near the front of the line of brain disorders that scientists believe might one day be treated with genome editing technologies such as CRISPR 1. By “treated,” they don’t mean just … |
PharmaTimes |
Incyte/MSD’s immunotherapy combo fails in Phase III
PharmaTimes A late stage trial testing Incyte’s epacadostat in combination with MSD’s Keytruda has failed to hit its primary targets in patients with unresectable or metastatic melanoma. The companies had been hoping that the combination of the IDO1 inhibitor and … Incyte Falls After Phase 3 Flop, But The Sky Isn’t FallingSeeking Alpha Incyte/Merck trial failure bodes ill for IDO classPMLiVE Incyte’s Epacadostat Fails in Melanoma Study, Shares PlungeNasdaq |
Reuters |
Novartis bets big on gene therapy with $8.7 billion AveXis deal
Reuters Narasimhan is counting on AveXis’s main drug, AVXS-101, for deadly spinal muscular atrophy (SMA), as well as the Illinois-based company’s gene therapy expertise and manufacturing capabilities, to bolster Novartis’s neuroscience business, one of the … |